Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EYPT

EYPT - EyePoint Pharmaceuticals Inc Stock Price, Fair Value and News

$13.20-0.83 (-5.92%)
Market Closed

14/100

EYPT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

14/100

EYPT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

EYPT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EYPT Price Action

Last 7 days

-16.2%

Last 30 days

2.7%

Last 90 days

-17.4%

Trailing 12 Months

93.3%

EYPT RSI Chart

EYPT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EYPT Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-4.75

Price/Sales (Trailing)

35.11

EV/EBITDA

-4.43

Price/Free Cashflow

-4.52

EYPT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

EYPT Fundamentals

EYPT Revenue

Revenue (TTM)

31.4M

Rev. Growth (Yr)

-94.65%

Rev. Growth (Qtr)

-35.75%

EYPT Earnings

Earnings (TTM)

-232.0M

Earnings Growth (Yr)

-63.31%

Earnings Growth (Qtr)

-13.19%

EYPT Profitability

EBT Margin

-726.14%

Return on Equity

-75.78%

Return on Assets

-63.73%

Free Cashflow Yield

-22.1%

EYPT Investor Care

Shares Dilution (1Y)

21.39%

Diluted EPS (TTM)

-3.17

EYPT Alerts

  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202556.0M51.9M42.3M31.4M
202450.0M50.4M45.7M43.3M
202339.8M37.3M42.5M46.0M
202238.9M41.5M42.4M41.4M
202134.3M39.2M32.5M36.9M
202025.8M22.8M35.9M34.4M
20195.7M12.2M14.2M20.4M
20182.9M3.0M3.1M4.6M
20176.1M7.5M7.6M2.6M
20167.9M1.6M3.1M4.6M
201526.4M26.6M20.3M14.1M
20143.7M3.5M28.2M28.1M
20132.4M2.1M2.2M2.2M
20126.5M3.5M2.4M2.4M
20119.5M5.0M6.1M6.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About EyePoint Pharmaceuticals Inc

EYPT
EyePoint Pharmaceuticals, Inc. focuses on developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The company's pipeline leverages its proprietary erodible Durasert E technology for sustained intraocular drug delivery, including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment, which is in Phase 2 clinical trials. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEhttps://eyepointpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES144

EyePoint Pharmaceuticals Inc Frequently Asked Questions

EYPT is the stock ticker symbol of EyePoint Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of EyePoint Pharmaceuticals Inc is 1.1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, EYPT's PE ratio (Price to Earnings) is -4.75 and Price to Sales (PS) ratio is 35.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EYPT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, EyePoint Pharmaceuticals Inc has provided -0.069 (multiply by 100 for percentage) rate of return.